St. Louis-born Galera's stock soars after release of positive study data for its experimental cancer therapy

Galera Therapeutics‘ stock price jumped 41% Thursday morning after the St. Louis-born biopharmaceutical company provided updated results from early-stage testing of its experimental therapy for advanced pancreatic cancer.